Is there a path forward for mGlu2 positive allosteric modulators for the treatment of schizophrenia?

Research output: Contribution to journalArticlepeer-review

27 Scopus citations


Two recent Phase II results show opposing outcomes for the potential of activators of mGlu2 in the treatment of schizophrenia. The first outcome revealed that Eli Lilly's mGlu2/3 agonist, pomaglumetad methionil (LY2140023), failed to meet the primary efficacy end point. The second report showed the mGlu2 positive allosteric modulator (PAM) from Addex (ADX71149) in conjunction with Janssen Research & Development met the primary objectives of safety, tolerability and demonstrated an effect on negative symptoms in patients.

Original languageEnglish (US)
Pages (from-to)211-213
Number of pages3
JournalACS Chemical Neuroscience
Issue number2
StatePublished - Feb 20 2013


  • Agonist
  • PAM
  • Phase II
  • mGlu
  • mGlu
  • positive allosteric modulator

ASJC Scopus subject areas

  • Biochemistry
  • Physiology
  • Cognitive Neuroscience
  • Cell Biology

Fingerprint Dive into the research topics of 'Is there a path forward for mGlu<sub>2</sub> positive allosteric modulators for the treatment of schizophrenia?'. Together they form a unique fingerprint.

Cite this